Levodopa-induced dyskinesias (LID) in Parkinson’s disease (PD) are frequent complications, and the endocannabinoid system has a role on its pathophysiology. To test the hypothesis that the functioning of the endocannabinoid system would be altered in PD and in LID by measuring plasma and CSF levels of α-N-arachidonoylethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG) in patients with PD with and without LID and in healthy controls. Blood and CSF samples were collected from 20 healthy controls, 23 patients with PD without LID, and 24 patients with PD with LID. The levels of AEA and 2-AG were measured using a highly sensitive column switching ultrahigh-performance liquid chromatography–tandem mass spectrometry method. When pooled together, patients with PD had lower plasma and CSF levels of 2-AG and higher CSF levels of AEA compared to healthy controls (Mann–Whitney statistics = 303.0, p = 0.02). Patients with PD without LID had lower CSF levels of 2-AG (Kruskal–Wallis statistics = 7.76, p = 0.02) and higher CSF levels of AEA levels than healthy controls (Kruskal–Wallis statistics = 8.81, p = 0.01). The findings suggest that the endocannabinoid system participates in the pathophysiology of PD symptoms, but its role in the pathophysiology of LID is still unclear.

帕金森病 (PD) 中左旋多巴引起的运动障碍 (LID) 是常见的并发症，内源性大麻素系统对其病理生理有一定作用。通过测量血浆和脑脊液中 α- N 的水平来检验内源性大麻素系统的功能会在 PD 和 LID 中改变的假设-花生四烯酰乙醇胺 (AEA) 和 2-花生四烯酰甘油 (2-AG) 在有和没有 LID 的 PD 患者和健康对照中。从 20 名健康对照、23 名无 LID 的 PD 患者和 24 名患有 LID 的 PD 患者收集血液和脑脊液样本。AEA 和 2-AG 的水平使用高灵敏度柱切换超高效液相色谱-串联质谱法测量。当合并在一起时，与健康对照相比，PD 患者的 2-AG 血浆和 CSF 水平较低，而 AEA 的 CSF 水平较高（Mann-Whitney 统计数据 = 303.0，p  = 0.02）。没有 LID 的 PD 患者的 CSF 中 2-AG 水平较低（Kruskal-Wallis 统计数据 = 7.76，p = 0.02) 且 AEA 水平的 CSF 水平高于健康对照（Kruskal-Wallis 统计数据 = 8.81，p  = 0.01）。研究结果表明，内源性大麻素系统参与了 PD 症状的病理生理学，但其在 LID 病理生理学中的作用尚不清楚。